Henderson William R, Dhingra Vinay K, Chittock Dean R, Fenwick John C, Ronco Juan J
Program of Critical Care Medicine, University of British Columbia, Vancouver Hospital and Health Sciences Centre, Vancouver, BC, Canada.
Intensive Care Med. 2003 Oct;29(10):1637-44. doi: 10.1007/s00134-003-1848-2. Epub 2003 Aug 12.
Brain injury remains the leading cause of death in cases of trauma in North America and Europe. This article critically appraised and summarised all published and peer-reviewed, randomised, controlled trials of the use of hypothermia in traumatic brain injury.
To be included, a study had to be a published, randomised, controlled trial of the use of hypothermia in the management of traumatic brain injury. Pooling of data and meta-analysis of results occurred.
Conducted at a tertiary level Canadian teaching hospital.
Patients were combined from eight randomised, controlled trials to generate a population of 748 severely head-injured patients.
Eight studies provided data on the efficacy of hypothermia in the management of traumatic brain injury. The pooled odds ratio of mortality in the hypothermic group was 0.81 (95%CI =0.59-1.13, p=0.22). The OR of a poor neurological outcome (GOS 1,2 or 3) was 0.75 (95% CI=0.56-1.01, p=0.06). The odds ratio for pneumonia in the normothermic group was 0.42 (95%CI =0.25-0.70, p=0.001).
Although meta-analysis suggests that iatrogenic hypothermia may confer a marginal benefit in neurological outcome, there does not appear to be clear evidence of lower mortality rates in unselected traumatic brain injury patients. Prolonged hypothermia may confer a benefit, particularly in patients with elevated intracranial pressure refractory to conventional manipulations. Conclusions regarding the use of hypothermia are controversial and not strongly supported by the available evidence.
在北美和欧洲,脑损伤仍是创伤病例中的主要死因。本文对所有已发表的、经过同行评审的、关于在创伤性脑损伤中使用低温疗法的随机对照试验进行了批判性评估和总结。
纳入的研究必须是已发表的、关于在创伤性脑损伤管理中使用低温疗法的随机对照试验。对数据进行了汇总并对结果进行了荟萃分析。
在加拿大一家三级教学医院进行。
患者来自八项随机对照试验,共纳入748例重度颅脑损伤患者。
八项研究提供了关于低温疗法在创伤性脑损伤管理中疗效的数据。低温治疗组的合并死亡比值比为0.81(95%可信区间=0.59-1.13,p=0.22)。神经功能预后不良(格拉斯哥预后评分1、2或3级)的比值比为0.75(95%可信区间=0.56-1.01,p=0.06)。常温治疗组肺炎的比值比为0.42(95%可信区间=0.25-0.70,p=0.001)。
尽管荟萃分析表明医源性低温可能在神经功能预后方面带来些许益处,但在未选择的创伤性脑损伤患者中,似乎没有明确证据表明死亡率更低。长时间低温可能有益,尤其是对于颅内压升高且对传统治疗方法无效的患者。关于使用低温疗法的结论存在争议,现有证据并未提供有力支持。